TY - JOUR T1 - Commercialized kit to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in Health Care Workers JF - medRxiv DO - 10.1101/2021.03.31.21254472 SP - 2021.03.31.21254472 AU - Mónica Martínez-Gallo AU - Juliana Esperalba-Esquerra AU - Ricardo Pujol-Borrell AU - Víctor Sandá AU - Iria Arrese-Muñoz AU - Candela Fernández-Naval AU - Andrés Antón-Pagarolas AU - Victoria Cardona AU - Moisés Labrador-Horrillo AU - Tomás Pumarola-Suñé AU - Manuel Hernandéz-González Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/08/2021.03.31.21254472.abstract N2 - Background It is crucial to assess the levels of protection generated by natural infection or SARS-CoV-2 vaccines, mainly in individuals professionally exposed and in vulnerable groups. Measuring T-cell responses may complement antibody tests currently in use as correlates of protection. Our aim was to assess the feasibility of a validated assay of T-cell responses.Methods Twenty health-care-workers (HCW) were included. Antibody test to SARS-CoV-2 N and S-proteins in parallel with a commercially available whole-blood-interferon-gamma-release-assay (IGRA) to S-peptides and two detection methods, CLIA and ELISA were determined.Results IGRA test detected T-cell responses in naturally exposed and vaccinated HCW already after first vaccination dose. The correlation by the two detection methods was very high (R>0.8) and sensitivity and specificity ranged between 100 and 86% and 100-73% respectively. Even though there was a very high concordance between specific antibody levels and the IGRA assay in the ability to detect immune response to SARS-CoV-2, there was a relatively low quantitative correlation. In the small group primed by natural infection, one vaccine dose was sufficient to reach immune response plateau. IGRA was positive in one, with Ig(S) antibody negative vaccinated immunosuppressed HCW illustrating another advantage of the IGRA-test.Conclusion Whole-blood-IGRA-tests amenable to automation and constitutes a promising additional tool for measuring the state of the immune response to SARS-CoV-2; they are applicable to large number of samples and may become a valuable correlate of protection to COVID-19, particularly for vulnerable groups at risk of being re-exposed to infection, as are health-care-workers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded in part by Instituto de Salud Carlos III, grant COV20/00416 co-financed by the European Regional Development Fund (ERDF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the Hospital Universitari Vall d,Hebron Institutional Clinical Ethical Board. (HUVH PR(AG)113/2021).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes27-March-2021(HCWs)Health care workers(IGRA)Interferon-gamma-release-assays(CLIA)Chemiluminescence immunoassays(ELISA)Enzyme linked immunosorbent assay(CBC)Complete blood count(S)Spike protein(N)Nucleocapsid protein ER -